SugenTech Expands Domestic Distribution of Allergy Diagnostic Products Developed as World's First

[Asia Economy Reporter Hyunseok Yoo] SuzenTech is intensifying its efforts to target the domestic allergy diagnostic market by partnering with a medical device specialist company.

On the 30th, SuzenTech announced that it has signed a domestic distribution agreement with ‘Handok,’ which has extensive experience and a wide distribution network in the domestic pharmaceutical and medical device markets, for the fully automated multiplex immunoblot device ‘S-blot3’ and the allergy diagnostic reagent ‘SGTi-Allergy screen.’

The fully automated multiplex immunoblot device ‘S-blot3’ integrates reagent pretreatment and analysis, and was developed by SuzenTech as the world’s first. It can simultaneously diagnose reactions to more than 100 allergy-inducing substances such as various foods and pollen using a small amount of blood.

The allergy diagnostic reagent SGTi-Allergy screen is the first allergy diagnostic product in Korea approved under the ‘In Vitro Diagnostic Medical Device Act’ enacted in 2019.

SuzenTech obtained manufacturing approval from the Ministry of Food and Drug Safety last October for the fully automated multiplex immunoblot device ‘S-blot3’ and the allergy diagnostic reagent SGTi-Allergy screen, and is currently selling them domestically. Through the distribution agreement with Handok, it plans to expand its domestic market share.

SuzenTech is also accelerating its efforts to secure a global market lead for allergy diagnostic products. Last October, it obtained European CE certification for the fully automated multiplex immunoblot device ‘S-blot3’ and the allergy diagnostic reagent ‘SGTi-Allergy screen,’ and is currently seeking global distribution networks based on this.

In particular, the allergy diagnostic market in China is in its infancy, and with recent considerations to lift birth restrictions, the child population is expected to steadily increase. Considering that the main patient group for tests such as atopy and allergies is children, the growth potential of the Chinese allergy diagnostic market is expected to be very high.

A SuzenTech official said, “The current global allergy diagnostic market is estimated to be about 3 trillion KRW, and it shows a high growth rate of over 10% annually due to rising income levels from accelerated economic development and global environmental issues.”

He added, “SuzenTech’s allergy diagnostic products, which incorporate over 10 years of technology and know-how, provide speed and convenience to domestic and international consumers, as well as excellent price competitiveness compared to existing products. We are also pursuing contracts in Europe, Southeast Asia, and the Middle East by utilizing the global distribution network secured through the supply of COVID-19 diagnostic kits.”

This content was produced with the assistance of AI translation services.